The healthcare sector remains a sweet spot for the stock market, ranked the most favored sector on the S&P 500 among Wall Street research firms, Reuters reported.

Rising drug prices have caught the attention of the Congressional Committee on Oversight and Reform, which announced it will open a “sweeping” drug price investigation.

A coordinated program to reduce fluoroscopy radiation resulted in a three- to eight-fold reduction in high-dose procedures performed over an eight-year period, according to a single-center study published Jan. 15 in Radiology.

Copayment vouchers for P2Y12 inhibitors modestly improved the likelihood that patients would continue taking the guideline-recommended medications for one year after myocardial infarction, according to a study published in JAMA. However, patients supplied with this financial assistance didn’t see a subsequent improvement in clinical outcomes.

Americans are concerned about higher drug costs impacting their wallets, but hospitals and health systems have also been feeling the pinch, according to a recent study from hospital groups including the American Hospital Association.

Scientists at Washington University in St. Louis are investigating if ultrasound-guided diffuse light tomography, a noninvasive imaging technique, could help radiologists differentiate cancers from benign tumors. This could lead to fewer unnecessary biopsies, the team believes, and reduce healthcare costs.

ST-segment elevation myocardial infarction (STEMI) survivors covered by Medicaid have lower rates of revascularization and higher rates of in-hospital mortality than their counterparts with private insurance, according to a study published in Circulation: Cardiovascular Quality and Outcomes.

The U.S. Preventive Services Task Force (USPSTF) has published a draft recommendation statement and draft evidence review that says clinicians should offer “risk-reducing medications” to women at an increased risk for breast cancer.